Sign Out
Pharmacotherapeutic Group: Tetanus toxoid. ATC Code: J07AM01.
Pharmacology: Pharmacodynamics: The active substance of the vaccine is purified tetanus toxoid (T) adsorbed on aluminium hydroxide. Toxoid is obtained by formaldehyde inactivation of tetanus toxin derived from Clostridium tetani culture.
Tetanus toxoid retains antigenic properties of the native toxin. Devoid of pathogenicity, it has strong antigenic properties and induces immune response which consists of production of specific antibodies, and triggers mechanisms which provide formation of immune memory. Immunizing properties of the vaccine are enhanced by aluminium hydroxide (adjuvant).
One dose of Tetana vaccine does not protect against infection with tetanus. After two to four weeks from the administration of the second dose of Tetana, or vaccines containing DT, Td antigens, and after the third dose of DTP (primary vaccination), 90% of patients develop the immunity. However, the immunity is short-lasting. The supplementary dose (the last dose of basic vaccination) provides immunity for 5 to 10 years.
Booster doses provide long-lasting protection against the disease.
Tetana complies with the requirements of the European Pharmacopoeia and WHO.
Pharmacokinetics: Not applicable.
Toxicology: Preclinical safety data: Prior to release, each production lot is a subject to specific toxicity analysis performed according to the European Pharmacopoeia requirements.
